Tenax Therapeutics, Inc.
TENX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000034956
In the last 90 days, Tenax Therapeutics, Inc. insiders filed 6 open-market purchases and 0 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $441.4M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Tenax Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +2 vs. Q4 2024
- Shares held
- 2.01M
- +644.2K (+47.3%) vs. Q4 2024
- Total value
- $13.1M
- +$4.69M (+55.6%) vs. Q4 2024
- New holders
- 4
- 5 more added
- Sold out
- 2
- 3 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TENX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 111 | $441.4M |
| Q1 2026 | 81 | $341.0M |
| Q4 2025 | 49 | $85.9M |
| Q3 2025 | 34 | $35.9M |
| Q2 2025 | 26 | $12.9M |
| Q1 2025 | 23 | $13.1M |
| Q4 2024 | 21 | $8.43M |
| Q3 2024 | 19 | $4.25M |
| Q2 2024 | 11 | $57.2K |
| Q1 2024 | 9 | $30.5K |
| Q4 2023 | 17 | $367.6K |
| Q3 2023 | 16 | $184.8K |
| Q2 2023 | 15 | $119.2K |
| Q1 2023 | 13 | $230.6K |
| Q4 2022 | 19 | $691.8K |
| Q3 2022 | 29 | $1.24M |
| Q2 2022 | 25 | $2.08M |
| Q1 2022 | 25 | $6.54M |
| Q4 2021 | 28 | $8.38M |
| Q3 2021 | 25 | $13.6M |
| Q2 2021 | 25 | $7.32M |
| Q1 2021 | 26 | $7.21M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Tenax Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 378,346 | $2.48M | 0.04% | +378,346 | New |
| BVF Inc | 339,549 | $2.22M | 0.09% | 00.0% | Unchanged |
| VR Adviser, LLC | 208,333 | $1.36M | 0.12% | 00.0% | Unchanged |
| Vivo Capital, LLC | 208,333 | $1.36M | 0.18% | 00.0% | Unchanged |
| Integral Health Asset Management, LLC | 167,000 | $1.09M | 0.12% | +167,000 | New |
| Janus Henderson Group PLC | 166,666 | $1.06M | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 121,094 | $793.2K | 0.00% | +46,649+62.7% | Added |
| Adage Capital Partners GP, L.L.C. | 83,333 | $545.8K | 0.00% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 83,333 | $545.8K | 0.56% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 68,741 | $450.3K | 0.09% | +34,048+98.1% | Added |
| Vestal Point Capital, LP | 53,439 | $350.0K | 0.02% | −1,750−3.2% | Reduced |
| Geode Capital Management, LLC | 33,341 | $218.4K | 0.00% | +8,987+36.9% | Added |
| Millennium Management LLC | 26,626 | $174.4K | 0.00% | −183−0.7% | Reduced |
| Citadel Advisors LLC | 23,141 | $151.6K | 0.00% | +23,141 | New |
| Vanguard Group Inc | 22,287 | $146.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 19,243 | $126.0K | 0.00% | −1,763−8.4% | Reduced |
| UBS Group AG | 2,893 | $18.9K | 0.00% | +2,890+96,333.3% | Added |
| BlackRock, Inc. | 300 | $1.97K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 229 | $1.50K | 0.00% | +201+717.9% | Added |
| Tower Research Capital LLC (TRC) | 192 | $1.26K | 0.00% | +192 | New |
| UMA Financial Services, Inc. | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 1 | $6 | 0.00% | 00.0% | Unchanged |
| Union Bancaire Privee, UBP SA | 1 | $6 | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −13,521−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −5−100.0% | Sold out |